查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1827611

女性健康診斷市場按適應症、檢測類型、技術、最終用戶、樣本類型和分銷管道分類—2025-2032 年全球預測

Women's Health Diagnostics Market by Disease Indication, Test Type, Technology, End User, Sample Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，女性健康診斷市場規模將成長至 984.3 億美元，複合年成長率為 9.73%。

主要市場統計數據
基準年2024年 468.2億美元
預計2025年 514.3億美元
預測年份：2032年 984.3億美元
複合年成長率（%） 9.73%

全面說明目前影響女性健康篩檢的動態，重點在於臨床重點、技術融合和相關人員

在日益融合的臨床需求、技術創新和不斷變化的醫療服務模式的推動下，女性健康診斷領域正在經歷持續的變化。臨床醫生、實驗室負責人和政策制定者正重新重視針對慢性病、感染疾病預防、代謝管理、癌症篩檢和生殖健康的早期發現、持續監測和以患者為中心的檢測策略。這些優先事項迫使診斷開發人員提供兼具臨床靈敏度、簡化工作流程和經濟實惠性的檢測方法和平台。

同時，分子檢測法、免疫檢測、生化分析和數位醫療領域的進步正在擴大可行診斷的範圍，超越傳統的中心實驗室模式。這些能力，加上分散式檢測、遠端醫療整合以及日益增多的照護現場部署等營運趨勢，強化了對強大的數據互通性和清晰的監管策略的需求。因此，在該領域運作的公司必須同時管理產品創新、製造彈性和市場准入，以滿足臨床醫生的期望和患者的需求。

隨著支付方和監管機構對臨床效用和實際表現的審查日益嚴格，開發人員不僅必須檢驗分析準確性，還必須驗證其對下游結果和工作流程的影響。這些因素的共同作用，為尋求擴展解決方案以有效改善女性在整個護理過程中的健康狀況的利益相關人員帶來了機會和複雜性。

改變女性健康診斷服務的關鍵顛覆性力量包括權力下放、分子創新、數位智慧和監管壓力

近期趨勢揭示了若干變革性變化，這些變化正在重塑女性健康診斷技術的開發、應用和報銷方式。科技的普及降低了照護現場設備和攜帶式平台的進入門檻，使得懷孕和不孕症標記檢測以及傳染病篩檢更加便捷。同時，在PCR工作流程改進和次世代定序方法引入的推動下，分子診斷技術正在為腫瘤學和感染疾病管理提供更高解析度的洞察，促使人們重新評估診斷演算法。

數據分析和人工智慧也在改變價值提案。演算法分類、多模態數據中的模式識別以及軟體驅動的決策支援正在提高複雜檢測的可解釋性，並實現篩檢間隔。不斷變化的法規和日益嚴格的付款人審查，同時迫使製造商更早投入，以產生真實世界證據，並展示超越傳統績效指標的臨床效用和經濟價值。地緣政治和供應鏈的考量正在進一步推動區域製造策略和供應商多元化，從而減少對單一來源的依賴。

由此產生的競爭格局將惠及那些能夠將強大的檢測能力與精簡的工作流程、清晰的監管途徑和可擴展的分銷模式相結合的機構。總而言之，這種轉變為跨部門合作、策略夥伴關係和定向投資創造了機會，使診斷創新與醫療保健服務的現實相契合。

評估2025年關稅對供應鏈、製造地決策、定價和採購行為的累積影響

2025年的關稅措施代表著重要的商業背景，正在再形成診斷製造商和經銷商的供應鏈經濟、採購行為和採購決策。某些類別的儀器和試劑進口關稅的提高，推高了依賴跨境製造的儀器和套件的到岸成本，給那些從國際採購零件的公司帶來了直接的利潤壓力。醫院、診斷中心和經銷商的採購團隊正在採取應對措施，加強供應商資格認證流程，並重新評估整體擁有成本，以在限制價格上漲的同時維持服務水準。

為了應對這項挑戰，一些製造商正在加快近岸外包和在岸外包的步伐，以保護關鍵生產環節免受關稅波動的影響。這種轉變不僅改變了資本規劃和位置，也影響了零件供應和契約製造的策略夥伴關係關係。定價策略也進行了調整，以平衡報銷現實與維持創新投資的需求，從而與付款人進行更細緻的商業性對話，將定價與臨床效果和營運效率聯繫起來。

在營運方面，不斷變化的關稅環境提升了模組化平台設計和試劑規格的價值，從而實現跨區域靈活生產。此外，庫存視覺性和需求平衡機制也日益重要，有助於緩解短期供應中斷。展望未來，在貿易緊張和監管環境不斷演變的環境下，積極拓展供應商網路、盡可能實現本地化生產並加強合約保護的利益相關人員將更有能力保持產品供應並保護利潤。

策略性細分洞察揭示了疾病適應症、檢測類型、技術、最終用戶、樣本類型和分銷管道如何影響機會和採用

深入的細分揭示了需求促進因素和技術選擇如何因疾病狀態、檢測形式和護理環境而異。在考慮疾病適應症時，心血管疾病、感染疾病、代謝性疾病、腫瘤學和懷孕/不孕症的優先順序有所不同；感染疾病著重於愛滋病毒和人類乳突病毒篩檢；代謝管理著重於糖尿病和甲狀腺疾病；腫瘤學投資著重於乳癌、子宮頸癌和卵巢癌的檢測；生殖健康需要便捷的排卵和懷孕檢測。這些臨床差異影響診斷所需的靈敏度、週轉時間和整合需求，並相應地塑造產品藍圖。

檢測類型進一步將市場機會細分為儀器、套件、試劑、軟體和服務。儀器包括桌上型和照護現場類型；套件和試劑包括免疫測量、橫向流動化驗和分子診斷套件；軟體和服務包括支援結果解讀和工作流程編排的資訊學軟體和服務。技術選擇涵蓋比色法和螢光法等生化測定、免疫檢測以及PCR和次世代定序等分子診斷，決定了分析性能、成本結構和易用性，從而影響不同最終用戶的採用曲線。

最終用戶本身涵蓋居家醫療機構、醫院、診斷中心和研究實驗室，每個機構都有其獨特的採購週期、研究預期和營運限制。檢體類型（血液、唾液、組織、尿液等）的考量決定了採集物流和檢測設計，而分銷管道（直銷、分銷商和線上管道）的動態則主導著產品上市和客戶參與策略。整合這些細分視角，可以實現更精準的產品定位、更有針對性的臨床檢驗，以及反映臨床工作流程和付款人需求的最佳商業化計畫。

區域比較洞察顯示法律規範、報銷實踐和本地製造如何影響全球主要地區的診斷採用

法律規範、支付系統和臨床實踐模式的地區差異，導致美洲、歐洲、中東和非洲以及亞太地區的商業化路徑截然不同。美洲通常受益於成熟的報銷機制和強大的私人診斷市場，一旦臨床效用得到證實，便可以相對快速地部署照護現場設備和新型分子檢測。該地區的採購通常強調與電子健康記錄和支援大型醫療保健系統的擴充性服務模式的整合。

歐洲、中東和非洲的環境更多元化，監管流程和報銷模式各異，需要在國家層級採取因地制宜的方案。一些歐洲市場可能透過協調監管和統一的臨床評估途徑來簡化實施流程，而中東和北非市場則可能優先考慮經濟高效的篩檢解決方案和能力建立夥伴關係，以擴大可及性。相關人員通常會尋求公私合營，以加快在資源匱乏地區的部署。

亞太地區正經歷已開發市場技術快速應用的快速發展，新興經濟體對價格合理、可擴展的診斷技術的需求也十分強勁。政府主導的舉措加強本地製造能力和國內供應夥伴關係的舉措是關鍵促進因素，而與區域經銷商的合作對於應對複雜的市場准入要求通常至關重要。在所有地區，了解監管時機、報銷途徑和臨床指南之間的相互作用對於有效的市場規劃和持續應用至關重要。

領先的診斷公司如何協調平台多樣化、試劑策略、數位服務和製造夥伴關係以保持成長和差異化

診斷生態系統中的主要企業正在採取各種策略來應對競爭壓力和臨床需求。儀器製造商優先考慮支援中央實驗室和照護現場流程的模組化平台，使其能夠透過一致的耗材生態系統服務眾多最終用戶。試劑和試劑套件製造商正在精簡其產品組合，轉向免疫測量和橫向流動裝置等大容量檢測方式，同時投資於利用簡化工作流程進行分散式檢查的分子試劑套件。

軟體和服務供應商正憑藉其連結性、決策支援和真實世界證據能力脫穎而出，這些能力有助於他們向臨床醫生和付款人展示其價值。整合數據分析和臨床檢驗程序的公司在支持付款人報銷談判和大型醫療系統採用方面具有優勢。同時，對於尋求減輕關稅影響並確保靈活生產能力的公司而言，製造外包製造商和區域合作夥伴正變得越來越重要。

策略合作、授權協議和選擇性收購仍然是快速填補能力缺口的常用機制，例如專業化檢測化學、數位健康專業知識和區域分銷網路。那些將研發投資與清晰的臨床效用路徑結合，並在生產和商業營運中保持嚴格執行的組織，最有能力將創新轉化為可擴展的業務成果。

為產業領導者提供切實可行的建議，以加強其供應鏈、加速平台採用、實現數據收益並最佳化其市場路線

產業領導者應採取一系列協同行動，抓住新機遇，同時降低下行風險。首先，透過多元化採購、選擇性近岸外包以及包含品質和交付保障措施的長期供應商協議，優先提升供應鏈韌性。加強庫存透明度和需求預測流程，將降低受關稅主導的成本衝擊和零件短缺影響的風險。其次，投資平台模組化和試劑標準化，將加快新檢測方法的上市時間，並以最少的檢驗實現跨市場部署。

第三，我們透過建構支持結果解讀、療效追蹤和證據產生的互通軟體，將數據策略融入產品開發。透過真實世界證據證明臨床效用對於有利的報銷討論和處方集收錄至關重要。第四，我們根據居家醫療、醫院、診斷中心和實驗室的需求客製化產品功能，並選擇能夠最大程度擴大覆蓋範圍並控制客戶體驗的銷售管道，從而客製化我們的市場推廣策略。最後，我們與臨床網路、公共衛生組織和區域製造商建立策略夥伴關係，以提高採用率、共用擔風險並加速規模化，同時滿足當地監管和付款方的要求。

採用初步訪談、二次綜合、資料三角測量、分割架構和品管等調查方法來指導分析

支撐這些見解的研究將定性專家參與與系統的二次分析相結合，以確保研究的深度和廣度。初步研究包括對臨床醫生、實驗室主任、採購專業人員和行業高管的結構化訪談，以了解臨床需求、工作流程限制和應用促進因素等領域的觀點。二次分析綜合了監管指南、報銷政策和近期同行評審文獻，以彙編臨床和技術趨勢。

採用資料三角測量法來協調不同觀點，並檢驗不同資訊來源的主題結論。疾病指徵、檢測類型、技術、最終用戶、樣本類型和分銷管道的細分框架指導了訪談指南和比較分析。品管方法包括訪談記錄的交叉檢驗、主題編碼的獨立審查以及檢測方法技術說明的檢驗。局限性包括監管時間表和不斷變化的關稅政策的地區差異，這些局限性通過定性解釋中基於情景的敏感性來解釋。這種方法強調透明度和調查方法的嚴謹性，以支持決策者得出可行的結論。

綜合結論，提取有關該領域的技術趨勢、臨床重點、商業性挑戰和策略要點的可行見解

摘要：女性健康診斷領域正朝著更分散化、數據驅動、臨床導向的解決方案轉型，以滿足傳染病篩檢、代謝監測、癌症檢測和生殖健康等領域的持續需求。分子診斷、免疫檢測和生化分析領域的技術進步擴展了診斷能力，而數位化工具則增強了解讀和護理整合。同時，政策變化、付款人預期以及關稅等貿易動態正迫使製造商調整其生產佈局、證據生成策略和商業性模式。

相關人員若能將產品設計與檢驗的臨床效用結合，推行彈性供應鏈策略，並採用可互通的數位服務，將能夠更好地將技術創新轉化為患者照護的重大改進。那些將科學嚴謹性與製造、監管和商業領域的實際執行力相結合，能夠在不斷發展的女性健康檢測領域產生持久影響的組織，將佔據優勢地位。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 具有人工智慧功能的穿戴式懷孕追蹤設備可提供個人化的排卵和週期預測，需求量很大
  • 在醫療資源匱乏的地區，基於遠端醫療的早期子癇前症篩檢就地檢驗的快速擴展
  • 整合非侵入性產前液態生物檢體檢測，全面檢測胎兒基因異常
  • 採用個人化多激素分析診斷來制定個人化的更年期管理計劃
  • 開發用於同時檢測多種性行為感染病原體的快速多重分子平台
  • 家用子宮內膜容受性測試的出現提高了 IVF 週期的植入成功率
  • 推出結合家庭樣本採集套件的遠端監控解決方案，用於女性心血管風險評估

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章：女性健康體檢市場（依疾病類型分類）

  • 心血管疾病
  • 感染疾病
    • HIV
    • 人類乳突病毒
  • 代謝紊亂
    • 糖尿病
    • 甲狀腺疾病
  • 腫瘤學
    • 乳癌
    • 子宮頸癌
    • 卵巢癌
  • 懷孕和生育能力
    • 排卵測試
    • 妊娠試驗

9. 女性健康檢查市場（按檢查類型）

  • 裝置
    • 桌上型裝置
    • 照護現場設備
  • 套件和試劑
    • 免疫檢測
    • 橫向流動化驗
    • 分子診斷試劑套件
  • 軟體和服務
    • 資訊軟體
    • 服務

第 10 章：女性健康檢查市場（按技術）

  • 生化分析
    • 比色分析
    • 螢光測量
  • 免疫檢測
  • 分子診斷
    • 次世代定序
    • PCR

第 11 章：女性健康體檢市場（依最終使用者）

  • 居家照護環境
  • 醫院和診斷中心
  • 研究辦公室

第 12 章：女性健康體檢市場（依樣本類型）

  • 血
  • 唾液
  • 組織
  • 尿

第13章女性健康體檢市場（依通路）

  • 直銷
  • 經銷商
  • 線上管道

第14章：女性健康體檢市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 女性健康體檢市場（依群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國女性健康體檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AccuBioTech Co., Ltd.
    • Becton, Dickinson and Company
    • Biomerieux SA
    • Cardinal Health, Inc.
    • Carestream Health, Inc.
    • Chembio Diagnostic Systems, Inc.
    • Cook Medical, Inc.
    • Danaher Corporation
    • DIALAB GmbH
    • EKF Diagnostics Holdings PLC
    • F. Hoffmann-La Roche Ltd.
    • FUJIFILM Holdings Corporation
    • GE Healthcare
    • Guided Therapeutics, Inc.
    • Hologic, Inc.
    • Koninklijke Philips NV
    • MedGyn Products, Inc.
    • NeuroLogica Corporation
    • Nova Biomedical
    • Perkinelmer Inc.
    • Quest Diagnostics Incorporated
    • Siemens AG
    • SuperSonic Imagine
    • Werfen, SA
    • OSI Systems, Inc.
    • Hill-Rom Holdings, Inc.
    • Bio-Rad Laboratories, Inc.
    • Sekisui Diagnostics, LLC
    • Thermo Fisher Scientific Inc.
Product Code: MRR-43477954269C

The Women's Health Diagnostics Market is projected to grow by USD 98.43 billion at a CAGR of 9.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 46.82 billion
Estimated Year [2025] USD 51.43 billion
Forecast Year [2032] USD 98.43 billion
CAGR (%) 9.73%

A comprehensive orientation to the current dynamics shaping women's health diagnostics with emphasis on clinical priorities, technology convergence, and stakeholder responsibilities

The landscape of women's health diagnostics is undergoing a period of sustained transition driven by converging clinical needs, technological innovation, and changing care delivery models. Clinicians, laboratory leaders, and policy makers are placing renewed emphasis on earlier detection, ongoing monitoring, and patient-centric testing strategies that address chronic conditions, infectious disease prevention, metabolic management, oncology screening, and reproductive health. These priorities exert pressure on diagnostic developers to deliver assays and platforms that combine clinical sensitivity with streamlined workflows and affordability.

Meanwhile, advances in molecular methods, immunoassays, biochemical analytics, and digital health are expanding the range of feasible diagnostics beyond traditional central laboratory paradigms. These capabilities are married to operational trends such as decentralization of testing, telehealth integration, and expanded point-of-care deployment, reinforcing the need for robust data interoperability and clear regulatory strategies. As a result, organizations operating in this space must simultaneously manage product innovation, manufacturing resilience, and market access pathways to meet clinician expectations and patient needs.

Because payers and regulators increasingly scrutinize clinical utility and real-world performance, developers must validate not only analytical accuracy but also downstream outcomes and workflow impacts. Taken together, these forces herald both opportunity and complexity for stakeholders seeking to scale solutions that meaningfully improve health outcomes for women across the care continuum.

Key disruptive forces transforming diagnostics delivery for women's health including decentralization, molecular innovation, digital intelligence, and regulatory pressure

Recent years have revealed several transformative shifts that are reshaping how diagnostics for women's health are developed, adopted, and reimbursed. Technological democratization has lowered barriers to entry for point-of-care instruments and portable platforms, enabling closer-to-patient testing for pregnancy and fertility markers as well as for infectious disease screening. At the same time, molecular diagnostics-driven by improvements in PCR workflows and adoption of next generation sequencing approaches-are producing higher-resolution insights for oncology and infectious disease management, prompting a reassessment of diagnostic algorithms.

Data analytics and artificial intelligence are also altering value propositions. Algorithmic triage, pattern recognition across multimodal data, and software-enabled decision support enhance the interpretability of complex assays and enable personalization of screening intervals. Concurrent regulatory evolution and payer scrutiny are prompting manufacturers to invest earlier in real-world evidence generation, demonstrating clinical utility and economic value beyond conventional performance metrics. Geopolitical and supply chain considerations have further accelerated regional manufacturing strategies and supplier diversification to reduce exposure to single-source dependencies.

As a result, the competitive environment rewards organizations that can integrate robust assay performance with streamlined workflows, clear regulatory pathways, and scalable distribution models. These shifts collectively create openings for cross-sector collaboration, strategic partnerships, and targeted investments that align diagnostic innovation with the practical realities of care delivery.

Assessing the cumulative implications of 2025 tariff actions on supply chains, manufacturing location decisions, pricing dynamics, and procurement behavior

The tariff measures implemented in 2025 present a material operating context that has reshaped supply chain economics, procurement behavior, and sourcing decisions for diagnostic manufacturers and distributors. Increased import duties on certain categories of instruments and reagents have elevated landed costs for devices and kits that rely on cross-border manufacturing, creating immediate margin pressure for firms that source components internationally. Procurement teams across hospitals, diagnostic centers, and distributors have responded by intensifying supplier qualification processes and re-evaluating total cost of ownership to retain service levels while limiting price escalation.

In response, several manufacturers have accelerated nearshoring and onshoring initiatives to insulate critical production stages from tariff volatility. This shift has not only altered capital planning and site selection but also influenced strategic partnerships for component supply and contract manufacturing. Pricing strategies have been adjusted to balance reimbursement realities with the need to preserve investment in innovation, prompting more nuanced commercial conversations with payers that link pricing to demonstrated clinical impact and operational efficiencies.

Operationally, the tariff environment has increased the value of modular platform designs and reagent formats that enable flexible manufacturing across geographies. It has also elevated the importance of inventory visibility and demand-smoothing mechanisms to mitigate short-term supply disruptions. Looking ahead, stakeholders that proactively diversify supplier networks, localize production where feasible, and strengthen contractual protections will be better positioned to sustain product availability and protect margin in an environment marked by trade friction and evolving regulatory landscapes.

Strategic segmentation insights clarifying how disease indications, test types, technologies, end users, sample types, and distribution channels shape opportunity and adoption

Insightful segmentation reveals how demand drivers and technology choices vary across disease states, test formats, and care settings. When considering disease indication, priorities differ between cardiovascular conditions, infectious diseases, metabolic disorders, oncology, and pregnancy and fertility, with infectious diseases receiving focused attention on HIV and human papillomavirus screening, metabolic management emphasizing diabetes and thyroid disorders, oncology investments targeting breast, cervical, and ovarian cancer detection, and reproductive health requiring accessible ovulation and pregnancy tests. These clinical distinctions influence the required sensitivity, turnaround time, and integration needs for diagnostics, and they shape product roadmaps accordingly.

Test type distinctions further refine market opportunities across instruments, kits and reagents, and software and services. Instruments vary between benchtop and point-of-care systems, while kits and reagents encompass immunoassays, lateral flow assays, and molecular diagnostics kits, and software and services include informational software and services that support result interpretation and workflow orchestration. Technology choices-spanning biochemical analysis modalities such as colorimetry and fluorometry, immunoassays, and molecular diagnostics including PCR and next generation sequencing-determine analytical performance, cost structure, and usability profiles, and therefore influence adoption curves across different end users.

End users themselves span home care settings, hospital and diagnostic centers, and research laboratories, each with unique procurement cycles, regulatory expectations, and operational constraints. Sample type considerations such as blood, saliva, tissue, and urine shape collection logistics and test design, while distribution channel dynamics across direct sales, distributors, and online channels govern market access and customer engagement strategies. Integrating these segmentation lenses enables more precise product positioning, targeted clinical validation, and optimized commercialization plans that reflect distinct clinical workflows and payer demands.

Comparative regional insights highlighting how regulatory frameworks, reimbursement practices, and local manufacturing shape diagnostics adoption across major global regions

Regional variation in regulatory frameworks, payer systems, and clinical practice patterns produces materially different commercialization pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, adoption commonly benefits from mature reimbursement mechanisms and a strong private diagnostics market, enabling relatively rapid uptake of point-of-care instruments and novel molecular assays when demonstrable clinical utility exists. Procurement in this region often emphasizes integration with electronic health records and scalable service models that support large health systems.

Europe, Middle East & Africa presents a more heterogeneous environment with divergent regulatory processes and reimbursement models, requiring tailored country-level approaches. Regulatory harmonization efforts and centralized clinical evaluation pathways in some European markets can streamline adoption, while markets in the Middle East and Africa may prioritize cost-effective screening solutions and capacity-building partnerships to expand access. Stakeholders frequently pursue public-private collaborations to accelerate deployment in under-resourced settings.

Asia-Pacific demonstrates a mix of rapid technological uptake in advanced markets and strong demand for affordable, scalable diagnostics across emerging economies. Local manufacturing capabilities and government-led initiatives to strengthen domestic supply chains are important dynamics, and partnerships with regional distributors are often critical to navigate complex market entry requirements. Across all regions, understanding the interplay between regulatory timing, reimbursement pathways, and clinical guidelines remains essential for effective market planning and sustainable adoption.

How leading diagnostics companies are aligning platform diversification, reagent strategy, digital services, and manufacturing partnerships to sustain growth and differentiation

Leading players across the diagnostics ecosystem are pursuing a range of strategic responses to competitive pressure and clinical demand. Instrument manufacturers are prioritizing modular platforms that support both central laboratory and point-of-care workflows, enabling them to serve multiple end users with a consistent consumable ecosystem. Reagent and kit producers are streamlining portfolio rationalization toward high-volume assay formats like immunoassays and lateral flow devices while investing in molecular kits that leverage simplified workflows for decentralized testing.

Software and service providers are differentiating through connectivity, decision support, and real-world evidence capabilities that help demonstrate value to clinicians and payers. Companies that integrate data analytics with clinical validation programs gain an advantage when negotiating payer reimbursement and when supporting adoption among large health systems. At the same time, contract manufacturers and regional partners are becoming more important as organizations seek to mitigate tariff exposure and secure flexible production capacity.

Strategic collaborations, licensing arrangements, and selectively targeted acquisitions remain common mechanisms to fill capability gaps quickly, whether for specialized assay chemistries, digital health expertise, or regional distribution networks. Organizations that align R&D investments with clear pathways to clinical utility and that maintain disciplined execution across manufacturing and commercial operations are best positioned to translate innovation into scalable business performance.

Actionable recommendations for industry leaders to strengthen supply chains, accelerate platform adoption, monetize data, and optimize market entry pathways

Industry leaders should enact a set of coordinated actions to capture emerging opportunities while reducing downside risk. First, prioritize supply chain resilience through diversified sourcing, selective nearshoring, and long-term supplier agreements that include quality and delivery safeguards. Strengthening inventory transparency and demand forecasting processes will reduce vulnerability to tariff-driven cost shocks and component shortages. Second, invest in platform modularity and reagent standardization to accelerate time-to-market for new assays and enable cross-market deployment with minimal revalidation.

Third, embed data strategies into product development by building interoperable software that supports result interpretation, outcomes tracking, and evidence generation. Demonstrating clinical utility through real-world evidence will be critical for favorable reimbursement discussions and formulary inclusion. Fourth, tailor market entry approaches by aligning product features with the needs of home care settings, hospital and diagnostic centers, and research laboratories, and by selecting distribution channels that maximize reach while controlling customer experience. Finally, pursue strategic partnerships with clinical networks, public health bodies, and regional manufacturers to amplify adoption, share risk, and accelerate scale while meeting local regulatory and payer requirements.

Research methodology describing primary interviews, secondary synthesis, data triangulation, segmentation frameworks, and quality controls that inform the analysis

The research underpinning these insights combined qualitative expert engagement with systematic secondary analysis to ensure both depth and breadth. Primary research involved structured interviews with clinicians, laboratory directors, procurement specialists, and industry executives to capture frontline perspectives on clinical needs, workflow constraints, and adoption drivers. Secondary analysis synthesized regulatory guidance, reimbursement policies, and recent peer-reviewed literature to contextualize clinical and technological trends.

Data triangulation was applied to reconcile differing viewpoints and to validate thematic conclusions across sources. Segmentation frameworks for disease indication, test type, technology, end user, sample type, and distribution channel guided interview targeting and comparative analysis. Quality control measures included cross-validation of interview transcripts, independent review of thematic coding, and verification of technical descriptions for assay methodologies. Limitations include variability in regional regulatory timelines and evolving tariff policies, which were accounted for through scenario-based sensitivity in qualitative interpretation. The approach emphasized transparency and methodological rigor to support actionable conclusions for decision-makers.

Concluding synthesis that distills actionable insights on technological trends, clinical priorities, commercial challenges, and strategic imperatives for the sector

In summary, the women's health diagnostics arena is moving toward more decentralized, data-enabled, and clinically focused solutions that respond to persistent needs in infectious disease screening, metabolic monitoring, oncology detection, and reproductive health. Technological advances in molecular diagnostics, immunoassay chemistry, and biochemical analysis are expanding diagnostic capability, while digital tools enhance interpretation and care integration. Meanwhile, policy shifts, payer expectations, and trade dynamics such as tariffs require manufacturers to adapt manufacturing footprints, evidence generation strategies, and commercial approaches.

Stakeholders that align product design with validated clinical utility, pursue resilient supply chain strategies, and embrace interoperable digital services will be well positioned to translate technical innovation into meaningful improvements in patient care. The path forward favors organizations that combine scientific rigor with pragmatic execution across manufacturing, regulatory, and commercial domains, enabling sustained impact in the evolving field of women's health diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for AI-enabled fertility tracking wearables providing personalized ovulation and cycle predictions
  • 5.2. Rapid expansion of telehealth-based point-of-care tests for early preeclampsia screening in underserved communities
  • 5.3. Integration of non-invasive prenatal liquid biopsy assays for comprehensive fetal genetic anomaly detection
  • 5.4. Adoption of personalized multi-hormone profiling diagnostics to tailor individualized menopause management plans
  • 5.5. Development of rapid multiplex molecular platforms for simultaneous detection of multiple sexually transmitted pathogens
  • 5.6. Emergence of at-home endometrial receptivity tests improving implantation success rates in in vitro fertilization cycles
  • 5.7. Implementation of telemonitoring solutions combined with at-home sampling kits for cardiovascular risk assessment in women

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Women's Health Diagnostics Market, by Disease Indication

  • 8.1. Cardiovascular Conditions
  • 8.2. Infectious Diseases
    • 8.2.1. HIV
    • 8.2.2. Human Papillomavirus
  • 8.3. Metabolic Disorders
    • 8.3.1. Diabetes
    • 8.3.2. Thyroid Disorders
  • 8.4. Oncology
    • 8.4.1. Breast Cancer
    • 8.4.2. Cervical Cancer
    • 8.4.3. Ovarian Cancer
  • 8.5. Pregnancy And Fertility
    • 8.5.1. Ovulation Test
    • 8.5.2. Pregnancy Test

9. Women's Health Diagnostics Market, by Test Type

  • 9.1. Instruments
    • 9.1.1. Benchtop Instruments
    • 9.1.2. Point Of Care Instruments
  • 9.2. Kits And Reagents
    • 9.2.1. Immunoassays
    • 9.2.2. Lateral Flow Assays
    • 9.2.3. Molecular Diagnostics Kits
  • 9.3. Software And Services
    • 9.3.1. Informational Software
    • 9.3.2. Services

10. Women's Health Diagnostics Market, by Technology

  • 10.1. Biochemical Analysis
    • 10.1.1. Colorimetry
    • 10.1.2. Fluorometry
  • 10.2. Immunoassay
  • 10.3. Molecular Diagnostics
    • 10.3.1. Next Generation Sequencing
    • 10.3.2. PCR

11. Women's Health Diagnostics Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospital And Diagnostic Centers
  • 11.3. Research Laboratories

12. Women's Health Diagnostics Market, by Sample Type

  • 12.1. Blood
  • 12.2. Saliva
  • 12.3. Tissue
  • 12.4. Urine

13. Women's Health Diagnostics Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Women's Health Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Women's Health Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Women's Health Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. AccuBioTech Co., Ltd.
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. Biomerieux SA
    • 17.3.5. Cardinal Health, Inc.
    • 17.3.6. Carestream Health, Inc.
    • 17.3.7. Chembio Diagnostic Systems, Inc.
    • 17.3.8. Cook Medical, Inc.
    • 17.3.9. Danaher Corporation
    • 17.3.10. DIALAB GmbH
    • 17.3.11. EKF Diagnostics Holdings PLC
    • 17.3.12. F. Hoffmann-La Roche Ltd.
    • 17.3.13. FUJIFILM Holdings Corporation
    • 17.3.14. GE Healthcare
    • 17.3.15. Guided Therapeutics, Inc.
    • 17.3.16. Hologic, Inc.
    • 17.3.17. Koninklijke Philips N.V.
    • 17.3.18. MedGyn Products, Inc.
    • 17.3.19. NeuroLogica Corporation
    • 17.3.20. Nova Biomedical
    • 17.3.21. Perkinelmer Inc.
    • 17.3.22. Quest Diagnostics Incorporated
    • 17.3.23. Siemens AG
    • 17.3.24. SuperSonic Imagine
    • 17.3.25. Werfen, S.A.
    • 17.3.26. OSI Systems, Inc.
    • 17.3.27. Hill-Rom Holdings, Inc.
    • 17.3.28. Bio-Rad Laboratories, Inc.
    • 17.3.29. Sekisui Diagnostics, LLC
    • 17.3.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. WOMEN'S HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. WOMEN'S HEALTH DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. WOMEN'S HEALTH DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD